Clareo Health | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically confirmed diagnosis of advanced and/or metastatic endometrial cancer with available tissue specimen (either archival tissue or fixed fresh biopsy)
Female patients ≥ 18 years old
Documented radiologically confirmed progression of disease after prior first-line treatment evidence of progressive disease
ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
At least one measurable lesion as per RECIST
You may not be if
Previous treatment with an FGFR inhibitor
More than one line of treatment for advanced or metastatic disease
Patients with uterine sarcomas, adenosarcoma, and malignant Mullerian tumors
Patients with isolated recurrences (vaginal, pelvic, or para-aortic) potentially curative with radiation therapy or surgery
